Kisspeptin-10 and PT-141 Together: What Is Known
Kisspeptin-10 and PT-141 taken together: what each one is, how each is regulated, and what is known about combining them.
Timing, interactions and safety
Evidence for the combination
No studies tested these together (PubMed search: 0 results, 2 Oct 2026).
Side by side
Showing 10 of 13 fields where the two differ. Category, PCAC vote, Jul 2026, Evidence strength are the same or both unknown.
| Field | Kisspeptin-10 | PT-141 |
|---|---|---|
| Class | GnRH stimulator | Melanocortin agonist |
| Also called | kiss | Vyleesi, PT141 |
| Category | Sexual & hormonal health | Sexual & hormonal health |
| FDA status | Not FDA approved · research chemical | FDA approved for HSDD (Vyleesi) |
| PCAC vote, Jul 2026 | Not on the Jul 2026 agenda | Not on the Jul 2026 agenda |
| WADA | Prohibited by WADA (S2.2.1)Kisspeptin and its agonist analogues are named in S2.2.1 (testosterone-stimulating peptides in males). | Not on the WADA Prohibited ListPT-141 (bremelanotide) is not named on the list and is FDA-approved (Vyleesi), so S0 does not apply. It does not fit the named S2 subclasses. |
| Anti-doping detection |
| None reportedanti-doping literature, as of 2 Oct 2026 |
| Half-life | mean elimination half-life 1.3-2.2 hourssubcutaneous (analog MVT-602) · Fertility and sterility 2024, PMID 37925096 | approximately 2.7 hours (range 1.9-4.0 h)subcutaneous · FDA label (Vyleesi) |
| Evidence strength | Human RCT evidence, 4 of 4Strongest: European journal of endocrinology 2026, PMID 42549827 | Human RCT evidence, 4 of 4Strongest: Journal of women's health 2022, PMID 35230162 |
| Human studies we summarised | 14 human (10 randomized or controlled) of 18 summarised | 12 human (12 randomized or controlled) of 12 summarised |
| Typical study doses |
|
|
| Vial sizes sold | 5 mg, 10 mg | 10 mg |
| Named in FDA warning letters, 2026 | Not in the letters we track | Yes (24 Aug 2026) |
Kisspeptin-10 vs PT-141
Choosing between the two rather than combining them? The comparison lines them up field by field.
PT-141 (bremelanotide) is an approved drug with phase 3 data
In the RECONNECT phase 3 trials, bremelanotide raised sexual desire scores in premenopausal women with HSDD versus placebo.[10]
The Vyleesi label says it may slow gastric emptying and reduce absorption of oral medicines.[8]
The label also flags an interaction with oral naltrexone: Vyleesi may significantly decrease its exposure.[8]
Kisspeptin: hormone-axis studies
Twice-weekly kisspeptin-54 for 8 weeks raised reproductive hormones in women with hypothalamic amenorrhoea.[13]
With subcutaneous kisspeptin-54, responses were significantly reduced by the 14th injection day.[14]
Adverse events on the PT-141 side
In the RECONNECT trials, nausea, flushing and headache were more frequent with bremelanotide than placebo, at 10% or more in both studies.[10]
Blood pressure on the PT-141 label
The Vyleesi label links doses taken close together with additive blood-pressure effects.[8]
Together
The kisspeptin-10 with bremelanotide search returned 0 PubMed records.
Calculated from pubmed query ("kisspeptin-10"[tiab] OR "kisspeptin 10"[tiab]) AND (bremelanotide[tiab] OR "PT-141"[tiab] OR PT141[tiab] OR Vyleesi[tiab]); search date 2026-10-02; records returned 0; records classed as study of the pair 0. Formula: Counts copied from the combinations dataset (web/src/data/combinations.json, key kisspeptin__pt-141); no arithmetic applied.
Drugs@FDA lists bremelanotide (PT-141) as Vyleesi, a prescription solution.[15]
Common questions
Kisspeptin vs PT-141 for libido: which works?
Only PT-141 has randomized trial data on sexual desire; kisspeptin's studies measure reproductive hormones.[10]
Can you take kisspeptin with PT-141?
No study tested the pair. The Vyleesi label notes it may slow gastric emptying and reduce absorption of oral medicines.[8]
Sources
- 1FDA warning letters to five research-peptide sellersFDA warning letter (NuScience Peptides; 1 of 5) · 2026fda.govAccessed 2 Oct 2026
- 2World Anti-Doping Code International Standard Prohibited List 2026World Anti-Doping Agency · 2026wada-ama.orgAccessed 2 Oct 2026
- 3[Not Available].Biomedical chromatography : BMC · 2024PMID 38978171Accessed 2 Oct 2026
- 4Analysis and Characterization of Kisspeptin and Its Analogues in Serum and Urine Samples by Liquid Chromatography-High-Resolution Mass Spectrometry for Doping Control Purposes.Drug testing and analysis · 2026PMID 42057309Accessed 2 Oct 2026
- 5Endocrine profile of the kisspeptin receptor agonist MVT-602 in healthy premenopausal women with and without ovarian stimulation: results from 2 randomized, placebo-controlled clinical tricals.Fertility and sterility · 2024PMID 37925096Accessed 2 Oct 2026
- 6Chronic subcutaneous kisspeptin-10 stimulates gonadotropin secretion for 12 days in healthy men.European journal of endocrinology · 2026PMID 42549827Accessed 2 Oct 2026
- 7Effects of Kisspeptin Administration in Women With Hypoactive Sexual Desire Disorder: A Randomized Clinical Trial.JAMA network open · 2022PMID 36287566Accessed 2 Oct 2026
- 8These highlights do not include all the information needed to use VYLEESI ® safely and effectively. See full prescribing information for VYLEESI VYLEESI (bremelanotide injection), for subcutaneous use Initial U.S. Approval: 2019FDA label (Vyleesi), DailyMed · current labeldailymed.nlm.nih.govAccessed 2 Oct 2026
- 9Prespecified and Integrated Subgroup Analyses from the RECONNECT Phase 3 Studies of Bremelanotide.Journal of women's health (2002) · 2022PMID 35230162Accessed 2 Oct 2026
- 10Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials.Obstetrics and gynecology · 2019PMID 31599840Accessed 2 Oct 2026
- 11Responder Analyses from a Phase 2b Dose-Ranging Study of Bremelanotide.The journal of sexual medicine · 2019PMID 31277966Accessed 2 Oct 2026
- 12PubMed search: ("kisspeptin-10"[tiab] OR "kisspeptin 10"[tiab]) AND (bremelanotide[tiab] OR "PT-141"[tiab] OR PT141[tiab] OR Vyleesi[tiab])PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 13Twice-weekly administration of kisspeptin-54 for 8 weeks stimulates release of reproductive hormones in women with hypothalamic amenorrhea.Clinical pharmacology and therapeutics · 2010PMID 20980998Accessed 2 Oct 2026
- 14Subcutaneous injection of kisspeptin-54 acutely stimulates gonadotropin secretion in women with hypothalamic amenorrhea, but chronic administration causes tachyphylaxis.The Journal of clinical endocrinology and metabolism · 2009PMID 19820030Accessed 2 Oct 2026
- 15Drugs@FDA (openFDA) search: active ingredient "bremelanotide"U.S. Food and Drug Administration · 2026api.fda.govAccessed 2 Oct 2026
Found an error? Report a correction.